Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention

Prior treatment

• Thrombolytic therapy within 24 hours of index PCI;
• Planned coronary revascularization (surgical or percutaneous) within 30 days;
• Required use of oral anticoagulation (warfarin or other factor II or factor X inhibitors);
• Participating in any other clinical trial of an investigational drug or device that has not met its primary endpoint.

Other illness

• Patients with active pathological bleeding (such as peptic ulcer or intracranial hemorrhage);
• History of intracranial hemorrhage, intracranial neoplasms, intracranial vascular malformations or hemangioma
• High potential risk of major bleeding, such as acute or chronic gastrointestinal ulcers or other gastrointestinal diseases, alignant tumors, etc.;
• Allergic to ticagrelor, clopidogrel or aspirin and any excipients;
• Diagnosed as active hepatitis or liver cirrhosis upon admission;
• Suffer from a known serious progressive disease (e.g. progressive cancer, chronic obstructive lung disease, etc.;) or estimated survival time\<12 months ;
• Dialysis-dependent renal failure；
• Any condition that may interfere with any study procedures, such as dementia, immobility, alcohol use, etc;

Lab values

• Platelet count\<100000 /mm3;

Other

• Implanted with first-generation DES or bioabsorbable stent(s) during hospitalization;
• Inability to tolerate 12-month DAPT (ticagrelor+aspirin) for any reason;
• Cardiogenic shock or hemodynamic instability;
• Pregnant or plan to be pregnant within 1 year;

• Age 18-80 years old;
• Acute coronary syndrome was diagnosed upon admission;
• Administered ticagrelor for at least 30 days after successful PCI with implantation of a current-generation drug-eluting stent(s)
• Agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent